• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year
Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year
Apr 16 2021

Cambridge, UK, 16th April 2021 We are delighted to announce that Sunil Shah of o2h ventures has won the prestigious award at the Cambridge Independent Science and Technology Awards as CEO of the Year. 

Sunil and his brother (co-founder) Prashant have been building the Anglo-India o2h Group together since 2003. They have built a scientifically driven ecosystem of ~350 people to support and invest into early stage therapeutic, AI driven biotech companies.  The o2h Group has research infrastructure and investments in Cambridge, UK and Ahmedabad, India with collaborations across three continents.

Stage is set for Cambridge Independent Science and Technology Awards

In Cambridge UK, o2h Group has been developing the newly named “Mill SciTech Park’ a 2.7 Acre plot, to the south of Cambridge with close connections to the other science parks, Addenbrooke’s Hospital and Astrazeneca HQ.  This site will allow o2h Ventures to invest and support companies as they form from its ‘Human Health SEIS Fund’ with the aim to build two ‘homegrown’ biotech companies per year. 

The flagship Human Health EIS Fund is now in its 2nd full year and has been followed with the launch of the first HMRC approved Knowledge Intensive fund and together with earlier Angel investments made by the brothers investments have been made in over 30 fledgling biotech companies many of which are based in Cambridge, including Exonate, Small Pharma, Arecor, Phoremost, Talisman, Spirea, Sentinel Oncology, Acacia, AI Vivo, Turbine, PharmEnable, Somaserve and Stemnovate. 

Sunil is a serial entrepreneur having begun his career in the Life Sciences team at Cambridge based PA Consulting group followed by an MBA at Cambridge University.  He has a passion for biotech, company creation and investing and he is on the board at Cambridge Angels, the Biotech Industry Association (BIA), as well as Chair/Board/Observer of Exonate, Metrion, In4Derm, Stingray Bio, Kuano and Oxford Drug Design.  He is the UKBAA 2019/20 Angel of the Year and won the ‘Special Recognition Award’ at the biotech industry leading OBN Awards 2019.

Sunil Shah, said “I am honored to win this award and accept this on behalf of both Prashant and I.  We are both hugely passionate entrepreneurs and love innovating and building.  I still feel that we are the beginning of our journey and have big plans to continue our journey of company creation, investing and providing support to the biotech companies that we work with.  We are very excited to open our doors at the Mill SciTech Park and continue our vision to build the most vibrant ecosystem to support early stage biotech companies. ” 

About Cambridge Independent 

The Cambridge Independent is an award-winning weekly newspaper and website published by Iliffe Media Ltd. It was first established as a newspaper in 1815 and was published until 1981. They aim to reflect the interests, concerns and views of the people who live here by creating distinctive, intelligent editorial, while offering effective advertising solutions. The team also writes, designs and prints niche publications to serve the community.

About the Science and Technology Awards 

The prestigious Science and Technology Awards are organised by the Cambridge Independent. With 15 categories for companies and individuals, last year’s awards promise another celebration of the Cambridge region’s extraordinary talent. The awards are now in their fourth year and have grown dramatically since their inception. They witnessed a celebration of the extraordinary. Innovation, ingenuity and exceptional talent were on display across 14 panels.

An independent judging panel, chaired by Cambridge Independent editor Paul Brackley, had the challenging task of examining well over 100 nominees to determine the winners and the highly commended entries.

A virtual ceremony, taking place in a bespoke interactive environment, was attended by leaders of businesses, organisations and research institutes across the Cambridge region.

About o2h Group

The o2h Group has two sites in Cambridge, UK and Ahmedabad, India and is made-up of three teams: o2h Ventures, o2h Discovery,  and o2h Technology.  The teams work together to support and invest into early stage biotech therapeutic companies and AI.

For more information about o2h ventures , please visit www.o2hventures.com

Media Contact : Ajit Singh

Marketing and PR, o2h ventures Ltd

ajit@o2h.com

 

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
recent press releases
  • o2h-ventures o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science 28 Feb 2023
  • o2h-ventures Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 Jan 2023
  • o2h-ventures o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 Jan 2023
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)